科研之友
微信
新浪微博
Facebook
分享链接
摘要
Aims: We investigated outcomes after discontinuing alpha-blockers or finasteride in patients who initially received combination therapy and compared differences by duration of combination therapy. Methods: Patients with international prostate symptom score 8, serum prostatic-specific antigen (PSA) %26lt;4ng/ml, prostate volume %26gt;25cm3 and combination therapy of alpha-blockers and finasteride for more than 6months were classified into three groups. Group 1 continued combination therapy; group 2, alpha-blockers monotherapy; and group 3, finasteride monotherapy. All parameters were evaluated before and after changing to monotherapy. Patients who received combination therapy for 69months and those who received combination therapy for longer were comparatively analysed. Results: Mean age of the 106 patients was 66.9 +/- 7.8years. No significant differences in baseline symptom scores, PSA or prostate volume were found. Following combination therapy, symptom scores, and quality of life (QoL) decreased for all groups. Group 1 maintained decreased PSA and prostate volume, and improved uroflowmetric profiles. No differences in uroflowmetric parameters were found after 6months. Group 2 maintained improved symptoms, QoL and uroflowmetric profiles, although PSA and prostate volume returned to baseline. Group 3 maintained lowered PSA and prostate volume, whereas Qmax returned to baseline. QoL scores showed no change. Patients who received combination therapy for 9months improved more in symptoms and QoL than those who received shorter combination therapy. Conclusions: Discontinuation of alpha-blockers or finasteride after combination therapy for 6months maintained improvements in symptoms. The appropriate period of combination therapy was 9months.
- 出版日期2013-4
